About Perosphere Pharmaceuticals
Perosphere Pharmaceuticals is a Healthcare company based in Danbury (United States) founded in 2011, and was acquired by AMAG Pharma in December 2018. Novel small molecule agents for anticoagulant reversal are developed. Perosphere Pharmaceuticals has raised $6.21 million across 1 funding round from investors including AMAG Pharma. Its focus areas include Life Sciences, Hematology, Drugs and Diversified. Its competitors include Keros Therapeutics, Jasper Therapeutics and Disc Medicine; 3 of its 3 listed competitors have raised funding.
Company details
Perosphere Pharmaceuticals is a specialty pharmaceutical company developing candidates that can re-establish normal blood coagulation in patients treated with anticoagulation drugs. Their lead candidate, ciraparantag (PER977) is a small synthetic water soluble NME which is intended for use as a reversal agent for the orally administered direct Factor Xa inhibitors and heparin is undergoing Phase 2 trials. The drug is being tested with anticoagulant products from Daiichi Sankyo, JJ, Bayer, BMS and Pfizer. The drug is FDA Fast Track designated. The company is also developing PER726, a drug targeting patients with status epilepticus (traumatic brain injury and are unresponsive to current therapies.
- Headquarters Danbury, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website perospherepharma.com
- Acquired by AMAG Pharma (Dec 2018)
- Total Equity Funding$6.21M (USD)
in 1 rounds
- Latest Funding Round$6.21M (USD), Series A
Feb 2016
- Investors
- Acquired byAMAG Pharma
(Dec 2018)
Funding Insights of Perosphere Pharmaceuticals
Perosphere Pharmaceuticals has successfully raised a total of $6.21M through 1 strategic funding round. The most recent funding activity was a Series A round of $6.21 million completed in February 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $6.21M
- Total Rounds 1
- Last Round Series A — $6.21M
- First Round $6.21M
(Feb 2016)
All 1 funding rounds of Perosphere Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2016 | $6.21M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Perosphere Pharmaceuticals
Perosphere Pharmaceuticals has secured backing from 1 investor. Prominent investors backing the company include AMAG Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Manufacturer of anemia based products and imaging agents for cancer and CVD diagnosis | 1981 | amagpharma.com | Waltham, United States |
Investor details for Perosphere Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Perosphere Pharmaceuticals
3 dated milestones of Perosphere Pharmaceuticals across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Perosphere Pharmaceuticals is founded.
- Funding First funding round of $6.2M.
- Exit Acquired by AMAG Pharma.
Competitors of Perosphere Pharmaceuticals
Perosphere Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Keros Therapeutics, Jasper Therapeutics and Disc Medicine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kerostx.com | 2016 | Lexington, United States | $90M | 136 | Small molecules are developed to treat hematologic and musculoskeletal disorders. | |
| jaspertx.com | 1999 | Redwood, United States | $84.1M | Developer of therapeutics for chronic diseases by targeting mast cells and stem cells | ||
| discmedicine.com | 2017 | Cambridge, United States | $140M | 23 | Developer of therapeutics for the treatment of hematologic diseases |
Detailed competitors of Perosphere Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Hematology
3 companies that operate in the same segment as Perosphere Pharmaceuticals (Hematology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Catheter-based thrombectomy devices for vascular emboli removal are developed. | 2011 | Irvine, California, United States | USD 51.89 M | USD 493.63 M | 696 | |
Small molecules are developed to treat hematologic and musculoskeletal disorders. | 2016 | Lexington, Kentucky, United States | USD 90 M | USD 244.06 M | 169 | |
Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders | 2016 | Menlo Park, California, United States | USD 300 M | 384 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Perosphere Pharmaceuticals
Complete news archive for Perosphere Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Perosphere Pharmaceuticals
Perosphere Pharmaceuticals was founded in 2011 and raised its 1st funding round 5 years after it was founded.
Perosphere Pharmaceuticals is headquartered in Danbury, United States. It is registered at Danbury, Connecticut, United States.
Perosphere Pharmaceuticals is a funded company, having raised a total of $6.21M across 1 funding round to date. The company's 1st funding round was a Series A of $6.21M, raised on Feb 2016.
Perosphere Pharmaceuticals is a specialty pharmaceutical company developing candidates that can re-establish normal blood coagulation in patients treated with anticoagulation drugs. Their lead candidate, ciraparantag (PER977) is a small synthetic water soluble NME which is intended for use as a reversal agent for the orally administered direct Factor Xa inhibitors and heparin is undergoing Phase 2 trials. The drug is being tested with anticoagulant products from Daiichi Sankyo, JJ, Bayer, BMS and Pfizer. The drug is FDA Fast Track designated. The company is also developing PER726, a drug targeting patients with status epilepticus (traumatic brain injury and are unresponsive to current therapies.
Perosphere Pharmaceuticals's top competitors include Keros Therapeutics, Disc Medicine and Jasper Therapeutics.
Perosphere Pharmaceuticals has 1 investor. Key investors include AMAG Pharma.
Yes. Perosphere Pharmaceuticals was acquired by AMAG Pharma in December 2018.